Brief: Maxcyte Sees 2025 Core Revenue To Grow 8% To 15%
12/03/2025 07:20
March 12 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE INC - FY24 NET LOSS $41.1 MILLION VERSUS LOSS OF $37.9 MILLION IN 2023 MAXCYTE INC - SEES 2025 CORE REVENUE TO GROW 8% TO 15% COMPARED TO 2024 Source text: ID:nRSL2752Aa Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026